OR WAIT null SECS
Medidata Solutions announced London-based Logos Technologies as a Medidata Technology Partner. An early-phase eSource data capture, trial management and clinical site automation specialist, Logos leveraged Medidata’s Web Services API to integrate data from its ALPHADAS Phase I solution with Medidata Rave, a system for capturing, managing, and reporting clinical research data. The completed integration enables the rapid transfer of Phase I data and metadata collected in ALPHADAS into Medidata Rave. Sponsors can benefit from Rave data management capabilities for Phase I trials and more easily view clinical data from all trial phases for a particular treatment in Rave.
ALPHADAS is a multi-study, schedule-driven, automated workflow system with staff and subject management tools, as well as barcoded sample tracking and management. It is designed to help sponsors and investigators around the world improve the speed, safety, quality and efficiency of Phase I trials, minimizing data queries while providing clean data in real time. A recent thorough QT study (TQT) study conducted at Spaulding Clinical Research in Westbend, Wis., showed that using ALPHADAS to collect and validate clinical data at the site produced virtually 100 percent accurate data. ALPHADAS also accepts patient data directly from clinical instrumentation, including vital sign systems, ECG devices and telemetry-based systems.
With this integration, sites can use ALPHADAS at the bedside, in the clinic and remotely, while sponsors benefit from a comprehensive view of a treatment’s trial data from all phases in one system, Medidata Rave. Moreover, with both the study metadata and study subject data captured in ALPHADAS rapidly moving to Rave, sponsors can take advantage of advanced Rave capabilities in data management, including easy query communication, coding and insightful reporting. The integration also enables sponsors using ALPHADAS for Phase I data capture to make use of Medidata Rave Safety Gateway, a configurable EDC-to-safety system interface that streamlines the reporting of serious adverse events by eliminating the need for duplicate data entry.
Logos Technologies joins the Medidata Technology Partner Program, which recognizes organizations with complementary technologies that support data sharing with Medidata products.
“Phase I research comes with unique challenges and workflow, and we’re always looking for ways to help sponsors improve that part of the process, whether it’s through our products or partnerships,” said Glen de Vries, president of Medidata Solutions. “Integrating with Logos allows ALPHADAS users to transition Phase I research into Medidata’s study management environment. Our joint customers will benefit from a rich set of data capture and management capabilities to handle their Phase I trials, as well as the ability to more easily view all study data in one system–Medidata Rave–for all phases of a study.”